Mirum Pharmaceuticals stock pulls back as Bank of America reveals new stake and valuation stays below 52-week high

Mirum Pharmaceuticals, Inc. stock (ISIN US60471A1034) ended the last completed trading day before September 20, 2026 at a Nasdaq price of USD 91.83, a level that underscores both recent volatility and a sizeable gap to the company’s 52-week high of USD 130.00 as investors reassess growth prospects and valuation.

Institutional interest and valuation signals

According to MarketBeat on September 20, 2026, shares of Mirum Pharmaceuticals opened at USD 91.83 on the preceding trading day, implying a market capitalization of around USD 5.96 billion and reflecting the company’s positioning as a mid-cap specialist in rare liver diseases.

The same overview notes that Mirum Pharmaceuticals has a 52-week low of USD 63.23 and a 52-week high of USD 130.00, which means the latest closing price sits roughly midway in that range and about 30 percent below the high, illustrating how far the stock would need to climb to revisit its peak levels from earlier in the year.

In its institutional ownership disclosure, MarketBeat reports that Bank of America Corp DE has initiated a new position in Mirum Pharmaceuticals, adding another large financial institution to the shareholder base and underlining that major investors remain willing to allocate capital to the stock despite recent price consolidation.

Analyst consensus and growth expectations

As highlighted by MarketBeat in its same September 20, 2026 snapshot, Mirum Pharmaceuticals stock currently carries a consensus rating of Moderate Buy, with an average analyst price target of USD 137.31 that stands more than 49 percent above the closing price of USD 91.83 and signals that covering analysts still see upside in the name.

The report also points out that Mirum Pharmaceuticals trades on a price-to-earnings ratio of minus 6.31, a figure that reflects the company’s loss-making status on a trailing basis and reminds investors that much of the valuation is anchored in expectations for future profitability rather than current earnings.

In addition, the stock’s beta of 0.49, cited by MarketBeat, suggests that Mirum Pharmaceuticals shares have historically moved less than the broader market, an important consideration for investors weighing the stock’s relatively defensive trading pattern against its still-elevated growth ambitions.

Technical backdrop and trading metrics

The same data snapshot from MarketBeat notes that Mirum Pharmaceuticals has a 50-day moving average price of USD 103.81 and a 200-day moving average price of USD 101.37, meaning the latest closing level of USD 91.83 sits more than USD 12 below the shorter moving average and nearly USD 10 under the longer trend line, a sign that the stock has recently been trading beneath key medium-term support levels.

For investors focused on trading metrics, Mirum Pharmaceuticals’ share price in the low 90-dollar range against a 52-week floor of USD 63.23 underscores that the stock remains substantially above last year’s lows, even after its retreat from the 130-dollar peak, which points to a still-constructive long-term price trend despite interim volatility.

While detailed same-day volume figures are not highlighted in the available week-filtered snapshots, the nearly USD 6 billion market capitalization and the presence of major institutional shareholders such as Bank of America provide an indication that the stock enjoys sufficient liquidity for most retail and many institutional trading strategies.

Recent corporate and insider activity

In addition to fund flows, MarketBeat notes that Mirum Pharmaceuticals’ chief executive officer Christopher Peetz sold 30,000 shares of the company earlier, at an average price of USD 98.68 for a total transaction value of USD 2,960,400.00, a move that investors may interpret in light of the stock’s subsequent decline to levels more than USD 6 below that sale price.

For shareholders tracking corporate governance and alignment, such insider transactions provide additional data points alongside institutional stake changes, helping to form a more nuanced view of how management and professional investors are positioning around Mirum Pharmaceuticals’ current valuation corridor.

Stock performance overview

Measured against its 52-week extremes, Mirum Pharmaceuticals stock at USD 91.83 as of the last completed trading day before September 20, 2026 remains USD 28.60 above its low of USD 63.23 while standing USD 38.17 below the high of USD 130.00, a spread that illustrates both the recovery from earlier troughs and the remaining distance to reclaim peak territory.

More news and analyses on Mirum Pharmaceuticals stock